Company: TVRD
Filing Date: 2025-10-20
Form Type: S-1/A
Source: 0001104659-25-100896
Chunk: 152

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-20
Form: S-1/A
Chunk 152
---
 31, 
 2024                    |   |         |   | ​ | ​ | 2023 |   |         |   | ​ 
 ​ |
|:-----------------------------------------------------|:--|:--|:-------------------------|:--|--------:|:--|:--|:--|:-----|:--|-------:|:--|:--|:--|:------------------------|:--|--------:|:--|:--|:--|:-----|:--|--------:|:--|:--|
| Net cash used in operating activities                | ​ | ​ | ​                        | $ | -13,557 | ​ | ​ | ​ | ​    | $ | -6,817 | ​ | ​ | ​ | ​                       | $ | -18,305 | ​ | ​ | ​ | ​    | $ | -21,040 | ​ | ​ |
| Net cash (used in) provided by investing activities  | ​ | ​ | ​                        | ​ | -20,433 | ​ | ​ | ​ | ​    | ​ |      — | ​ | ​ | ​ | ​                       | ​ |       — | ​ | ​ | ​ | ​    | ​ |  22,468 | ​ | ​ |
| Net cash (used in) provided by financing activities  | ​ | ​ | ​                        | ​ |  23,024 | ​ | ​ | ​ | ​    | ​ |      5 | ​ | ​ | ​ | ​                       | ​ |  27,000 | ​ | ​ | ​ | ​    | ​ |       2 | ​ | ​ |
| Net (decrease) increase in cash and cash equivalents | ​ | ​ | ​                        | $ | -10,966 | ​ | ​ | ​ | ​    | $ | -6,812 | ​ | ​ | ​ | ​                       | $ |   8,695 | ​ | ​ | ​ | ​    | $ |   1,430 | ​ | ​ |

Operating Activities Net cash used in operating activities was $13.6 million for the six months ended June 30, 2025, reflecting a net loss of $5.4 million, non-cash changes of $6.5 million, and changes in operating assets and liabilities of $1.6 million. The changes of $6.5 million in non-cash expenses were primarily driven by $7.8 million related